Charlotte Robinson

DocwireNews

Sparsentan was granted accelerated approval in the United States for use in adults with primary immunoglobulin A nephropathy (IgAN) based on results of the phase 3 PROTECT trial. The study included 404 patients &ge;18 years old with biopsy-proven IgAN, urine protein excretion of &ge;1.0 g/day, and estimated glomerular filtration rate (eGFR) of &ge;30 mL/min/1.73 m2. They were randomized 1:1 to receive sparsentan 400 mg/day or irbesartan 300 mg/day for up to 110 weeks.A group of researchers led by Jonathan Barratt examined efficacy results from the final analysis of the PROTECT double-blind period (approximately 2 years). They presented their findings in an abstract at the International Society of Nephrology World Congress of Nephrology 2024.At 110 weeks, compared with irbesartan, sparsentan demonstrated sustained reductions in urine protein-to-creatinine ratio (UPCR), with a 40% relative reduction versus irbesartan and long-term kidney function preservation. The results consistently favored sparsentan across subgroups; larger effects were observed with higher baseline proteinuria. In the total study population, treatment with sparsentan led to a statistically significant reduction in the rate of eGFR decline over weeks 6 to 110 (chronic slope) compared with irbesartan (difference, 1.1 mL/min/1.73 m2/year; P=.037). The difference in the rate of eGFR decline from day 1 to week 110 (total slope) with sparsentan versus irbesartan was 1.0 mL/min/1.73 m2/year (P=.058).In their final analysis, the researchers found that sparsentan had a clinically meaningful benefit on long-term kidney preservation, with absolute change in eGFR and rate of eGFR change favoring sparsentan over irbesartan across baseline proteinuria subgroups over 2 years. &ldquo;These results may significantly impact the treatment landscape of patients with IgAN,&rdquo; they said.Source: <a href="https://doi.org/10.1016/j.ekir.2024.02.1413" target="_blank" rel="noopener">KI Reports</a>

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Latest News

Sparsentan Shows Benefits Over Irbesartan for IgAN

WCN 2024

Researchers found that sparsentan had a clinically meaningful benefit on long-term kidney preservation versus irbesartan in patients with immunoglobulin A nephropathy (IgAN). 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe